ClinicalTrials.gg
Not yet recruitingNCT07560033Updated Apr 30, 2026

A Comparative Pharmacokinetic Study of CM326 in Healthy Subjects

A Phase 1 interventional study of CM326(formulation 1) and CM326(formulation 2) in Healthy Subjects, sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd.. Not yet recruiting. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-30.

Sponsored by CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
192
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

This is a randomized, open-label, parallel-controlled study to compare the PK, safety, and immunogenicity of CM326 administered via different delivery devices in healthy subjects.

02

Conditions studied

  • Healthy Subjects
03

In context

Lead sponsor

CSPC Baike (Shandong) Biopharmaceutical Co., Ltd. is the lead sponsor of 26 studies on the registry; 4 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants [c1.1]must be informed of the study before it begins, fully understand the study content, procedures, and potential adverse reactions, and voluntarily sign the written ICF;
  2. Healthy male participants aged 18 to 55 years;
  3. Body weight between 55.0 and 85.0 kg, and between 19.0 and 26.0 kg/m²;
  4. Physical examination, vital signs, 12-lead , laboratory tests, and other examination results are normal, or abnormal but without clinical significance;
  5. Participants and their partners agree to use effective and reliable methods from signing the ICF until 3 months after dosing;
  6. Participants are able to communicate well with the investigator, and to understand and comply with the requirements of the study.

Exclusion criteria

Exclusion Criteria:

  1. History of chronic diseases or severe diseases involving the circulatory system, blood or hematopoietic system, respiratory system, endocrine system, urinary system, digestive system, immune system, psychiatric or nervous system, reproductive system, etc.;
  2. Presence or suspicion of any active viral, bacterial, fungal, or parasitic infection within 14 days before dosing;
  3. Participants who have undergone major surgery within 3 months before screening, or who plan to undergo major surgery during the study period;
  4. History of allergies to drugs, food, etc., or Participants who may be allergic to the study drug or its components in the Investigator's judgment;
  5. Positive result for any of the following: surface antigen, antibody, Treponema pallidum antibody, antigen/antibody;
  6. History of drug abuse, or use of illicit drugs within 3 months before screening, or habitual use of any psychotropic drugs (including herbal medicines), or a positive urine drug screen;
  7. Blood loss or blood donation of more than 200 mL within 3 months before screening;
  8. Intolerance to subcutaneous injection, or presence of abdominal scars that affect subcutaneous administration, and any skin abnormalities and/or tattoos that may affect the safety assessment of the injection site;
  9. Use of any prescription drugs, over-the-counter drugs, herbal medicines or vitamin and dietary supplements within 14 days or 5 half-lives (whichever is longer) before dosing;
  10. Use of any marketed or biological products within 6 months or 5 half-lives (whichever is longer) before dosing;
  11. Participants who have previously used CM326 or drugs targeting TSLP;
  12. Vaccination within 4 weeks before screening, or plan to receive such vaccines during the study;
  13. Participation in any clinical trial within 3 months before screening;
  14. Average daily smoking of more than 5 cigarettes within 3 months before screening, or unwilling to avoid using any tobacco products during the study;
  15. Regular alcohol consumption within 3 months before screening, defined as weekly alcohol consumption exceeding 14 units (1 unit = 360 mL of 5% alcohol beer or 45 mL of 40% alcohol spirits or 150 mL of 12% alcohol wine), or inability to stop alcohol intake during the study, or a positive blood alcohol test;
  16. Regular consumption of excessive amounts of tea, coffee, and/or caffeinated beverages within 3 months before screening;
  17. Participants who have special dietary requirements and are unable to comply with the standardized diet;
  18. History of needle phobia or hemophobia, or d difficulty with venipuncture or unable to tolerate venous puncture;
  19. Participants who, in the Investigator's judgment, may be unable to complete the study for other reasons or are considered unsuitable for enrollment.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
192 participants (estimated)

Study arms

  • Experimental
    CM326 group 1

    Subjects will receive a single subcutaneous injection of CM326 on Day 1.

    Drug: CM326(formulation 1)

  • Experimental
    CM326 group 2

    Subjects will receive a single subcutaneous injection of CM326 on Day 1.

    Drug: CM326(formulation 2)

Interventions

06

What researchers measure

Primary outcomes

  1. Maximum concentration (Cmax)

    To compare the Cmax of CM326 administered via different delivery devices

    Time frame: Pre-dose at day 1 to Day 113

  2. Area under the concentration-time curve from zero to infinity (AUCinf)

    To compare the AUCinf of CM326 administered via different delivery devices

    Time frame: Pre-dose at day 1 to Day 113

Secondary outcomes

  1. Time to maximum concentration (Tmax)

    To characterize the Tmax of CM326 in healthy subjects

    Time frame: Pre-dose at day 1 to Day 113

  2. Area under the concentration-curve from zero to the last quantifiable concentration (AUClast)

    To characterize the AUClast of CM326 in healthy subjects

    Time frame: Pre-dose at day 1 to Day 113

  3. Terminal elimination half-life (t1/2)

    To characterize the t1/2 of CM326 in healthy subjects

    Time frame: Pre-dose at day 1 to Day 113

  4. Apparent clearance (CL/F)

    To characterize the Vz/F of CM326 in healthy subjects

    Time frame: Pre-dose at day 1 to Day 113

  5. Apparent volume of distribution (Vz/F)

    To characterize the Vz/F of CM326 in healthy subjects

    Time frame: Pre-dose at day 1 to Day 113

  6. Number of subjects with adverse events as Assessed by CTCAE v6.0

    To assess the safety of CM326 in healthy subjects

    Time frame: Pre-dose at day 1 to Day 113

  7. Incidence of ADA

    To assess the immunogenicity of CM326 in healthy subjects

    Time frame: Pre-dose at day 1 to Day 113

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Apr 2026; primary completion for Oct 2026, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 30, 2026
StartEst.
Apr 20, 2026
Primary completionEst.
Oct 1, 2026
CompletionEst.
Dec 31, 2026
Last update
Apr 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07560033
Responsible party
Sponsor
First posted
Apr 30, 2026
Start date
Apr 20, 2026 (estimated)
Primary completion
Oct 1, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Apr 30, 2026

Study contacts

Clinical Trials Information Group officer
Contact
ctr-contact@cspc.cn
+86-0311-69085587
Wei Hu
Contact
huwei@ahmu.edu.com
+86-13856086475

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocankitug

Start the discussion